Patient characteristics and treatment
Cisplatin-eligible patients with cT2–T4aN0M0 MIBC received treatment with four cycles of gemcitabine and cisplatin plus nivolumab (Extended Data Fig. Between 8 August 2018 and 24 November 2020, 76 patients were enrolled with baseline characteristics as detailed in Table Baseline patient characteristics (